ALK-positive anaplastic large cell lymphoma
MONDO:0017602ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) is a type of ALCL, a rare and aggressive peripheral T-cell non-Hodgkin lymphoma affecting lymph nodes and extranodal sites, which is characterized by the expression of a protein called anaplastic lymphoma kinase (ALK).
Also known as: ALCL, ALK+, ALK+ ALCL, ALK+ anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, ALKoma, anaplastic large cell lymphoma, ALK-positive
1961 clinical trials for this condition and its sub-types, 22 tagged with ALK-positive anaplastic large cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Can a smart immune cell with a kill switch beat tough lymphomas?
Cure Not yet recruitingThis Phase 1 trial tests a new type of cell therapy for people with relapsed or refractory CD30-positive lymphomas, including Hodgkin lymphoma and certain non-Hodgkin lymphomas. The treatment uses a patient's own immune cells that are genetically engineered to recognize and attac…
Phase 1 • Sponsor: The Methodist Hospital Research Institute • Aim: Cure
Last updated Jul 29, 2026 00:00 UTC
-
New study aims to tame cholesterol side effect of lung cancer drug
Disease control Not yet recruitingThis study looks at the best way to manage high cholesterol caused by the targeted therapy lorlatinib in people with advanced ALK-positive non-small cell lung cancer. Some participants receive standard cholesterol-lowering drugs, while others get a more intensive combination. The…
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC